Tag

Semaglutide

All articles tagged with #semaglutide

health23 hours ago•5 min saved

GLP-1 drugs linked to longer lifespans in mice, early sign of aging slowdown

A Berkeley study found the GLP-1 drug semaglutide (the active ingredient in Ozempic/Wegovy/Rybelsus) increased lifespan in mice by about 12% (roughly 100 days), along with reductions in aging hallmarks and better muscle and cognition. In a calorie-restriction comparison, drug-treated mice showed some advantages beyond weight loss, suggesting GLP-1s may affect aging pathways beyond calories. However, results are in mice and may not translate to humans yet; further research is needed to assess potential human benefits for lifespan and healthspan.

via New York Post|

#aging #glp-1 #health

science1 day ago•11 min saved

Late-life GLP-1 drug extends lifespan in female mice, hints at anti-ageing effects

Treating aging female mice of an inbred strain with the GLP-1 receptor agonist semaglutide late in life improves physiological function, slows several ageing hallmarks, and extends lifespan, suggesting anti-ageing benefits beyond calorie restriction.

via Nature|

#aging #glp-1 #lifespan

science1 day ago•6 min saved

Glucose-Lowering Drug Semaglutide May Reduce Bipolar Hospitalizations

A Swedish nationwide study led by Griffith University found that bipolar patients using semaglutide (Ozempic/Wegovy) had a 21% lower risk of psychiatric hospitalization compared to periods without GLP-1 medications, with the effect not observed for other GLP-1 drugs like liraglutide or dulaglutide. The researchers suggest potential brain-wide benefits beyond metabolism, possibly via anti-inflammatory or cellular-stress pathways, and call for randomized trials to confirm whether semaglutide could become part of bipolar care to reduce relapse risk.

via scitechdaily.com|

#bipolar-disorder #bipolar-treatment-research #glp-1-receptor-agonists

science1 day ago•6 min saved

GLP-1 obesity drug extends lifespan in ageing female mice

Older female mice given the GLP-1 obesity drug semaglutide lived longer and showed healthier ageing markers; while calorie intake dropped, matching-calorie controls did not fully explain the benefits, indicating potential anti-ageing effects that are not yet proven in humans.

via Nature|

#ageing #glp-1 #lifespan

science1 day ago•52 min saved

GLP-1R activation late in life extends lifespan and mitigates aging in aged female mice

Late-life treatment of 20‑month‑old female mice with the GLP‑1R agonist semaglutide reduced food intake and significantly extended median lifespan, while improving locomotion, cognition, and glucose control. Semaglutide also alleviated multiple aging hallmarks—e.g., inflammation, cellular senescence, genomic instability, and mitochondrial dysfunction—and promoted neurogenesis. Transcriptomic analyses showed activation of nutrient-sensing pathways and sirtuins, aligning with calorie restriction cues. In a direct comparison, semaglutide mimicked many calorie restriction benefits and offered additional improvements in exploration, memory, and metabolic health, supporting GLP-1R activation as a calorie restriction mimetic with potential anti-aging effects in humans.

via Nature|

#aging #calorie-restriction-mimetic #glp-1-receptor

health2 days ago•4 min saved

Microdosing GLP-1 Weight Drugs: Small Wins, Uncertain Safety, Limited Evidence

A new observational study suggests that microdosing Wegovy (semaglutide) and Zepbound (tirzepatide) can lead to some weight loss, but far less than full-dose regimens and with different side effects; causation isn’t established. Over a year, low-dose tirzepatide users lost about 5.5% of body weight and low-dose semaglutide users about 2.2%, versus 20.2% and 13.7% in higher-dose trials. Side effects varied by drug and dose, with kidney-related issues and GI symptoms more common for tirzepatide, and ear inflammation, sweating, and ankle swelling more common for semaglutide. The study is observational and relies on electronic health records and AI-curated notes, so it cannot prove benefits or harms. Medical guidance emphasizes that weight loss at low doses is limited and decisions should be made with a healthcare provider; drugmakers continue to recommend gradual dose escalation to maintenance doses.

via USA Today|

#glp-1 #health #microdosing

health2 days ago•17 min saved

Wegovy extends mouse lifespan, fueling anti-ageing discussions

A study found the weight‑loss drug Wegovy (semaglutide) extended lifespans by about 12% in healthy‑weight female mice starting at 20 months, with signs of reduced inflammation, DNA damage and cellular senescence, suggesting potential anti‑ageing effects beyond weight loss. Experts caution that results in mice may not translate to humans, noting sex and species differences, possible side effects, and cost; more research is needed before any anti‑ageing use.

via The i Paper|

#ageing #health #longevity

health8 days ago•9 min saved

Oral TOFA Triggers Fat Burn, Preserves Muscle, and Boosts Obesity Drugs in Mice

A preclinical study in obese mice shows the oral compound TOFA reduces body weight by about 18% without changing food intake or causing muscle loss, by both limiting fat production and increasing cellular energy expenditure (about 18%). TOFA also improves fatty liver disease and blood lipid markers. When combined with obesity drugs like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound), the cotreatments outperform single drugs and maintain weight loss longer after treatment ends, suggesting a complementary mechanism that could enhance current therapies. Human safety and dosing remain unknown, and the work is limited to animal models.

via StudyFinds|

#fatty-liver-disease #health #metabolism

health9 days ago•4 min saved

Ozempic Shows Promise for Mood Stability in Bipolar Disorder

Australian researchers analyzed 15,000 people over 15 years and found that semaglutide (Ozempic) lowered the risk of psychiatric hospitalization in bipolar disorder by about 21%, a benefit not seen with related GLP-1 drugs. The findings suggest GLP-1 signaling may protect the brain by reducing inflammation and cellular stress, potentially improving mood stability, though more research is needed to confirm direct effects on bipolar symptoms.

via New York Post|

#bipolar-disorder #glp-1 #health

health16 days ago•6 min saved

Tirzepatide Might Trigger More Hair Loss Than Semaglutide, Early Study Suggests

A preprint study comparing tirzepatide (Zepbound/Mounjaro) with semaglutide (Ozempic/Wegovy) in 8,985 women found higher incident alopecia with tirzepatide (5.44% vs 3.63%). At six months, 1.55% vs 1.24%; at twelve months, 4.20% vs 2.88%. After adjusting for weight loss, hair loss remained more common with tirzepatide (4.24% vs 3.33%), suggesting weight loss alone doesn’t explain the difference. The study is observational and not yet peer‑reviewed. Experts note GLP-1 meds can cause temporary shedding, and persistent patches should be evaluated by a dermatologist; patients should not stop their medication without physician guidance. The differing receptor targets (GIP/GLP-1 for tirzepatide vs GLP-1 alone for semaglutide) may influence the hair follicle environment, but mechanisms are not yet clear.

via Women's Health|

#alopecia #glp-1 #hair-loss

health19 days ago•16 min saved

GLP-1 obesity drugs offer early hope for PMOS, a hormonal disorder

GLP-1 obesity medications, including semaglutide, are showing early promise in treating PMOS by promoting weight loss, improving insulin resistance, and balancing hormones to support ovulation. Small studies led by Dr. Melanie Cree, including a Colorado patient who saw slowed hair growth, normalized periods, and significant weight loss, suggest potential benefits for PMOS patients. However, insurance coverage remains a major hurdle since PMOS is not an approved indication for these drugs and results vary, highlighting the need for more research and access solutions.

via KSL.com|

#glp-1 #health #hormone-balance

science20 days ago•5 min saved

GLP-1 Weight Drugs May Weigh on Fat Use, Not Just Appetite

A new mouse study suggests long-term weight loss from GLP-1 drugs like Ozempic and Wegovy may rely not only on suppressing appetite but also on energy mobilization governed by AgRP hunger neurons. When these neurons were disrupted in female mice, semaglutide still reduced eating, but fat mobilization and the overall weight-loss effect weakened, leading to weight regain within about two weeks. Normal-functioning neurons maintained weight loss, and disruptions involving Sirt1 signaling partially reversed the effect. Results are preclinical and observed mainly in female mice, so more research is needed to understand implications for humans.

via ScienceAlert|

#agrp-neurons #glp-1 #mice-study

health21 days ago•4 min saved

VA Launches Largest GLP-1 Trial to See if Semaglutide Reduces Alcohol Cravings in Veterans

The Department of Veterans Affairs is launching the largest study to test whether the GLP-1 drug semaglutide can curb alcohol cravings in more than 600 veterans with alcohol use disorder, aiming to produce definitive evidence that could lead to FDA label changes and broader prescribing in primary care. The trial compares semaglutide to placebo with brief medical management sessions and regular health assessments, building on earlier studies showing GLP-1 medications can reduce heavy drinking and total drinks.

via Task & Purpose|

#alcohol-use-disorder #fda #glp-1

entertainment24 days ago•16 min saved

Chrissy Metz Flaunts Strength Gains After GLP-1 Weight-Loss Reveal

Chrissy Metz posted a “progress report” after going public with her GLP-1 journey, showing off a flexed bicep in an Instagram Story and crediting strength training for part of her 100-pound weight loss; she hasn’t disclosed which medication she’s taking or for how long, says therapy and diets didn’t work for her, defends personal medical choices against critics, and notes perimenopause and family obesity as context.

via Page Six|

#chrissy-metz #entertainment #glp-1

health28 days ago•13 min saved

UK Records Near-200 Deaths Linked to GLP-1 Weight-Loss Drugs, Regulator Cautions on Causation

UK MHRA Yellow Card data show roughly 200 deaths linked to GLP-1 obesity drugs (about 59 with semaglutide Ozempic/Wegovy, 120 with tirzepatide Mounjaro, 37 with liraglutide Saxenda) and over 150,000 adverse reactions. The regulator notes that reportings do not prove causation and many deaths may be due to underlying illnesses, while emphasizing GLP-1 medicines are safe for the majority of users; examples in investigations include deaths of Caroline Savage and Paula Owen.

via The Times of India|

#adverse-reactions #glp-1-weight-loss-drugs #health